Novartis patent xolair?

What patents does Novartis have for Xolair (omalizumab)?

Xolair (omalizumab) is the brand name for the anti-IgE monoclonal antibody used for allergic asthma and other allergic conditions. Patent coverage for Xolair is complex because it can include multiple patents covering the drug substance, formulations, delivery/device aspects, and additional indications over time.

To see the specific patent numbers and status for Xolair, DrugPatentWatch.com tracks related filings and exclusivity/patent timelines by country and document. [1]

When does Xolair’s patent/exclusivity end?

The exact end date depends on the jurisdiction (for example, U.S. vs. EU vs. other markets) and which specific patent or regulatory exclusivity period you mean. Search typically turns up different dates because:
- separate patents can expire at different times, and
- regulatory exclusivities (in some regions) can extend market protection beyond the first patent expiry.

DrugPatentWatch.com is one place to check the mapped timeline for Xolair by region and patent entry. [1]

Why do people look up “Novartis patent Xolair” during biosimilar/generic searches?

Patent end dates are often used to estimate when competitors can launch:
- biosimilars (for biologics like omalizumab), and/or
- authorized competitor products in specific markets.

Because multiple patents may still be active even after some coverage ends, launch timing can change based on which patents are challenged and which courts uphold. Patent-watch sites compile these publication and status signals for planning. [1]

Where can I find the most up-to-date Xolair patent list?

For a current, searchable compilation of Xolair-related patent entries (including country-by-country status), use DrugPatentWatch.com here: [1]

Sources

1. DrugPatentWatch.com – Xolair (omalizumab) patents